Cyxone AB (publ) (CYXO.ST)
SEK 0.02
(0.0%)
SEK 0.02
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 2.61 Million SEK | -37.21% |
| 2022 | 4.15 Million SEK | 331.77% |
| 2021 | -1.79 Million SEK | 0.11% |
| 2020 | -1.79 Million SEK | 94.87% |
| 2019 | -35.02 Million SEK | -10.21% |
| 2018 | -31.78 Million SEK | -387.93% |
| 2017 | -6.51 Million SEK | -56.67% |
| 2016 | -4.15 Million SEK | -2466.53% |
| 2015 | -162 Thousand SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 367 Thousand SEK | -83.89% |
| 2024 Q1 | 2.27 Million SEK | 642.02% |
| 2023 Q2 | 263 Thousand SEK | -66.92% |
| 2023 Q1 | 795 Thousand SEK | -86.25% |
| 2023 FY | 2.61 Million SEK | -37.21% |
| 2023 Q4 | 307 Thousand SEK | 148.42% |
| 2023 Q3 | -634 Thousand SEK | -341.06% |
| 2022 FY | 4.15 Million SEK | 331.77% |
| 2022 Q3 | -616 Thousand SEK | -10.0% |
| 2022 Q4 | 5.78 Million SEK | 1038.64% |
| 2022 Q2 | -560 Thousand SEK | -24.72% |
| 2022 Q1 | -449 Thousand SEK | 0.0% |
| 2021 Q1 | -449 Thousand SEK | 0.0% |
| 2021 Q2 | -449 Thousand SEK | 0.0% |
| 2021 Q3 | -449 Thousand SEK | 0.0% |
| 2021 FY | -1.79 Million SEK | 0.11% |
| 2021 Q4 | -449 Thousand SEK | 0.0% |
| 2020 Q4 | - SEK | 0.0% |
| 2020 Q1 | - SEK | 0.0% |
| 2020 FY | -1.79 Million SEK | 94.87% |
| 2020 Q2 | - SEK | 0.0% |
| 2020 Q3 | - SEK | 0.0% |
| 2019 Q4 | - SEK | 0.0% |
| 2019 FY | -35.02 Million SEK | -10.21% |
| 2019 Q3 | - SEK | 0.0% |
| 2019 Q2 | - SEK | 0.0% |
| 2019 Q1 | - SEK | -100.0% |
| 2018 Q1 | - SEK | 100.0% |
| 2018 FY | -31.78 Million SEK | -387.93% |
| 2018 Q2 | - SEK | 0.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2018 Q4 | 1000.00 SEK | 0.0% |
| 2017 Q1 | - SEK | 100.0% |
| 2017 Q2 | - SEK | 0.0% |
| 2017 FY | -6.51 Million SEK | -56.67% |
| 2017 Q3 | - SEK | 0.0% |
| 2017 Q4 | -6.51 Million SEK | 0.0% |
| 2016 Q4 | -714 Thousand SEK | 15.6% |
| 2016 Q1 | - SEK | 0.0% |
| 2016 FY | -4.15 Million SEK | -2466.53% |
| 2016 Q2 | - SEK | 0.0% |
| 2016 Q3 | -846 Thousand SEK | 0.0% |
| 2015 FY | -162 Thousand SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -160.68 Million SEK | 101.625% |
| Ziccum AB (publ) | -23.28 Million SEK | 111.213% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 346.31 Million SEK | 99.246% |
| Sprint Bioscience AB (publ) | 41.78 Million SEK | 93.752% |
| Mendus AB (publ) | 28.48 Million SEK | 90.834% |
| Genovis AB (publ.) | 54 Million SEK | 95.165% |
| Intervacc AB (publ) | -13.79 Million SEK | 118.929% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | -20.267% |
| Active Biotech AB (publ) | -1.67 Million SEK | 255.881% |
| Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | 73.793% |
| Bio-Works Technologies AB (publ) | 26.82 Million SEK | 90.265% |
| Aptahem AB (publ) | 2.63 Million SEK | 0.747% |
| Vicore Pharma Holding AB (publ) | -3.42 Million SEK | 176.323% |
| Kancera AB (publ) | -1.96 Million SEK | 232.875% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -3290.909% |
| Fluicell AB (publ) | 1.73 Million SEK | -50.23% |
| Saniona AB (publ) | 11.78 Million SEK | 77.837% |
| Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | 151.026% |
| Biovica International AB (publ) | 6.87 Million SEK | 62.033% |
| Spago Nanomedical AB (publ) | -23.28 Million SEK | 111.214% |
| AcouSort AB (publ) | 8.38 Million SEK | 68.876% |
| Xintela AB (publ) | 78 Thousand SEK | -3247.436% |
| Abliva AB (publ) | -35.66 Million SEK | 107.321% |
| Egetis Therapeutics AB (publ) | -146.9 Million SEK | 101.777% |
| Karolinska Development AB (publ) | 2.8 Million SEK | 6.983% |
| OncoZenge AB (publ) | 3000.00 SEK | -86933.333% |
| Amniotics AB (publ) | -1.93 Million SEK | 235.285% |
| 2cureX AB (publ) | -37.48 Million SEK | 106.965% |
| CombiGene AB (publ) | -21.29 Million SEK | 112.264% |
| Asarina Pharma AB (publ) | -423 Thousand SEK | 717.258% |
| Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 99.769% |
| Camurus AB (publ) | 1.58 Billion SEK | 99.835% |
| Corline Biomedical AB | 28.38 Million SEK | 90.8% |
| IRLAB Therapeutics AB (publ) | -122.73 Million SEK | 102.127% |
| Isofol Medical AB (publ) | -34.41 Million SEK | 107.587% |
| I-Tech AB | 27.56 Million SEK | 90.528% |
| Hansa Biopharma AB (publ) | 70.95 Million SEK | 96.32% |
| ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | 23.274% |
| Biosergen AB | -456 Thousand SEK | 672.588% |
| Cantargia AB (publ) | -3.45 Million SEK | 175.659% |
| NextCell Pharma AB | -43.74 Million SEK | 105.968% |
| Xspray Pharma AB (publ) | -9.19 Million SEK | 128.399% |
| Elicera Therapeutics AB (publ) | 11.21 Million SEK | 76.726% |
| Nanologica AB (publ) | -76 Thousand SEK | 3535.526% |
| SynAct Pharma AB | -778 Thousand SEK | 435.604% |
| Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | 1452.85% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | -12.92 Million SEK | 120.206% |
| Lipum AB (publ) | 53 Thousand SEK | -4826.415% |
| BioInvent International AB (publ) | 71.46 Million SEK | 96.346% |
| Alzinova AB (publ) | 19.87 Million SEK | 86.862% |
| Oncopeptides AB (publ) | 36.29 Million SEK | 92.807% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -78.466% |
| Guard Therapeutics International AB (publ) | -15 Thousand SEK | 17506.667% |
| Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | -57.479% |
| Simris Alg AB (publ) | 2 Million SEK | -30.095% |
| Diamyd Medical AB (publ) | -3.58 Million SEK | 172.933% |
| Xbrane Biopharma AB (publ) | 35.38 Million SEK | 92.622% |
| Ascelia Pharma AB (publ) | -1.04 Million SEK | 348.904% |
| Diagonal Bio AB (publ) | 3.13 Million SEK | 16.661% |